for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nippon Kayaku Co Ltd

4272.T

Latest Trade

1,370.00JPY

Change

5.00(+0.37%)

Volume

241,600

Today's Range

1,370.00

 - 

1,377.00

52 Week Range

1,097.00

 - 

1,450.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Nippon Kayaku to merge with units

Aug 28(Reuters) - Nippon Kayaku Co Ltd <4272.T>:Says it plans to merge with a wholly owned Hiroshima-based unit and a wholly owned Tokyo-based unit.Merger effective Oct. 1.Says the two units will be dissolved after the merger .

R&I affirms Nippon Kayaku's rating at "A" and says stable outlook-R&I

June 5 (Reuters) - Nippon Kayaku Co Ltd <4272.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A"-R&I.Rating outlook stable-R&I .

Chugai Pharmaceutical says waiver of claims in patent infringement lawsuit

April 11 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it has decided to waive its claim in a patent infringement lawsuit against Nippon Kayaku Co Ltd <<<4272.T>>>.Says co filed a lawsuit to the Tokyo District Court on Aug. 17, 2017, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® Injection 60 and 150 (Herceptin® Injection) against Nippon Kayaku, the applicant for marketing approval of the biosimilar of Herceptin® Injection, citing such party's infringement of the application patents for the treatment of breast cancer owned by Genentech Inc.

Nippon Kayaku initiates phase II clinical trials on NK105 for treatment of breast cancer

Feb 21 (Reuters) - Nippon Kayaku Co Ltd <4272.T>:Says it initiated phase II clinical trials on NK105 for treatment of breast cancer .

Nippon Kayaku unit acquires 100 pct stake in RaySpec

Dec 27(Reuters) - Nippon Kayaku Co Ltd <4272.T>:Says its consolidated subsidiary Polatechno Co Ltd <<<4239.T>>> acquired 100 percent stake in the United Kingdom-based firm RaySpec Limited, on Dec. 26.

Chugai Pharmaceutical says lawsuit on patent infringement concerning Herceptin® injection and petition for provisional disposition order

Sept 8 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says co has filed a lawsuit and a petition for provisional disposition order against Nippon Kayaku Co.,Ltd <<<4272.T>>>, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® injection 60 and 150 (Herceptin® injection) .Genentech Inc, a U.S.-based firm, is a patent holder and co is the exclusive licensee of Herceptin® injection .Says co and Genentech are the co-plaintiff of the lawsuit.

R&I affirms Nippon Kayaku's rating at "A" and announces stable outlook-R&I

May 25 (Reuters) - Nippon Kayaku Co Ltd <4272.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A" -R&I.Says rating outlook stable -R&I.

Nippon Kayzku completes share repurchase

Nippon Kayzku Co Ltd <4272.T>: Says it completed repurchase of 1.4 million shares of its common stock, from May 1 to May 26 . Says shares repurchased is 1.53 billion yen in total .Says previous plan disclosed on Nov. 5, 2015.

Nippon Kayaku updates share repurchase status

Nippon Kayaku <4272.T>: Says it repurchased 1,033,000 shares for 1,146,918,000 yen in total from April 1 to April 30 . Says this was part of the share repurchase plan announced on Nov. 5, 2015 .Says accumulatively repurchased 6,561,000 shares for 7,956,229,000 yen in total as of April 30.

Nippon Kayaku updates share repurchase status

Nippon Kayaku Co Ltd:Repurchased 1,075,000 shares for 1,206,412,000 yen in total from March 1 to March 31.Says this was part of the share repurchase plan announced on Nov. 5, 2015.Says accumulatively repurchased 5,528,000 shares for 6,809,311,000 yen in total as of March 31.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up